Novartis has renewed its pursuit of Parkinson’s disease treatments by licensing a preclinical RNA interference therapy from Arrowhead Pharmaceuticals, centered on silencing the alpha-synuclein gene implicated in disease progression. The agreement includes a $200 million upfront payment with potential milestones exceeding $2.2 billion. Arrowhead’s TRiM platform enables delivery of RNAi therapies, including ARO-SNCA targeting central nervous system targets. Novartis aims to develop this therapy alongside other candidates in collaboration with Arrowhead, marking a strategic investment in neurodegeneration treatment modalities. This effort follows prior setbacks by other companies targeting Parkinson's disease and represents a high-stakes bet on RNA-based therapeutics.